Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P43489
UPID:
TNR4_HUMAN
Alternative names:
ACT35 antigen; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor
Alternative UPACC:
P43489; Q13663; Q2M312; Q5T7M0
Background:
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40L receptor, ACT35 antigen, and TAX transcriptionally-activated glycoprotein 1 receptor, plays a pivotal role in immune system regulation. It serves as a receptor for TNFSF4/OX40L/GP34, enhancing long-term T-cell immunity and acting as a receptor for human herpesvirus 6B/HHV-6B.
Therapeutic significance:
TNFRSF4's involvement in Immunodeficiency 16, a condition marked by poor T-cell recall immune responses and susceptibility to classic Kaposi sarcoma, underscores its therapeutic potential. Targeting TNFRSF4 could lead to innovative treatments for this immunodeficiency and other T-cell related disorders.